Advertisement
Screener

Cognition Therapeutics, Inc. (CGTX) Increase (Decrease) in Other Receivables

2.8 / 5 stars · 68/120 Roast Me

Cognition Therapeutics, Inc. Increase (Decrease) in Other Receivables

Cognition Therapeutics, Inc. (CGTX) reported Increase (Decrease) in Other Receivables of -$467.00 thousand for the 12-month period ending 2022-12-31, per its 10-K filed 2024-03-26.

Discontinued › Cash Flow › Operating Activities

us-gaap:IncreaseDecreaseInOtherReceivables · last filed 2024-03-26

  • Cognition Therapeutics, Inc. increase (decrease) in other receivables for the quarter ending 2022-12-31 was -$2.00K, a 101.40% decline year-over-year.
  • Cognition Therapeutics, Inc. increase (decrease) in other receivables for the quarter ending 2022-09-30 was $2.00K, a 92.00% decline year-over-year.
  • Cognition Therapeutics, Inc. increase (decrease) in other receivables for the quarter ending 2022-06-30 was $0.00.
  • Cognition Therapeutics, Inc. increase (decrease) in other receivables for the quarter ending 2022-03-31 was -$467.00K, a 841.27% decline year-over-year.
  • Cognition Therapeutics, Inc. increase (decrease) in other receivables for fiscal 2022 was -$467.00K.
  • Cognition Therapeutics, Inc. increase (decrease) in other receivables for fiscal 2021 was -$121.00K.
  • Cognition Therapeutics, Inc. increase (decrease) in other receivables for fiscal 2020 was -$904.00K.
Period endIncrease (Decrease) in Other Receivables 3 monthIncrease (Decrease) in Other Receivables 6 monthIncrease (Decrease) in Other Receivables 9 monthIncrease (Decrease) in Other Receivables 12 month
2022-12-31-$2.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-26
$0.00
derived: sum of 2 quarters · filed 2024-03-26
$0.00
derived: sum of 3 quarters · filed 2024-03-26
-$467.00K
10-K · filed 2024-03-26
2022-09-30$2.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02
$2.00K
derived: sum of 2 quarters · filed 2023-11-02
-$465.00K
10-Q · filed 2023-11-02
-$322.00K
derived: sum of 4 quarters · filed 2023-11-02
2022-06-30$0.00
derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09
-$467.00K
10-Q · filed 2022-08-09
-$324.00K
derived: sum of 3 quarters · filed 2023-03-23
-$299.00K
derived: sum of 4 quarters · filed 2023-03-23
2022-03-31-$467.00K
10-Q · filed 2022-05-11
-$324.00K
derived: sum of 2 quarters · filed 2023-03-23
-$299.00K
derived: sum of 3 quarters · filed 2023-03-23
-$651.00K
derived: sum of 4 quarters · filed 2023-03-23
2021-12-31$143.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-23
$168.00K
derived: sum of 2 quarters · filed 2023-03-23
-$184.00K
derived: sum of 3 quarters · filed 2023-03-23
-$121.00K
10-K · filed 2023-03-23
2021-09-30$25.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14
-$327.00K
derived: sum of 2 quarters · filed 2022-11-14
-$264.00K
10-Q · filed 2022-11-14
-$202.00K
derived: sum of 4 quarters · filed 2022-11-14
2021-06-30-$352.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09
-$289.00K
10-Q · filed 2022-08-09
-$227.00K
derived: sum of 3 quarters · filed 2022-08-09
2021-03-31$63.00K
10-Q · filed 2022-05-11
$125.00K
derived: sum of 2 quarters · filed 2022-05-11
2020-12-31$62.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-30
-$904.00K
10-K · filed 2022-03-30
2020-09-30-$966.00K
10-Q · filed 2021-11-17

Similar stocks

Stock NameCountryMarket CapPE Ratio
Pelthos Therapeutics Inc. (PTHS)United States$0.086B-1.20
Atara Biotherapeutics, Inc. (ATRA)United States$0.086B-6.48
Vaxart, Inc. (VXRT)United States$0.080B3.84
Cardiff Oncology, Inc. (CRDF)United States$0.101B-2.22
Kalaris Therapeutics, Inc. (KLRS)United States$0.073B-2.19
Black Diamond Therapeutics, Inc. (BDTX)United States$0.109B-2.48
CHAMPIONS ONCOLOGY, INC. (CSBR)United States$0.070B-68.02
BioStem Technologies, Inc. (BSEM)United States$0.069B
Eloxx Pharmaceuticals, Inc. (ELOX)United States$0.065B
LENZ Therapeutics, Inc. (LENZ)United States$0.117B-1.41